Herpes medications work by blocking the virus’s ability to copy its own DNA, which stops it from multiplying inside your cells. They don’t kill the virus or remove it from your body, but they slow the infection enough for your immune system to regain control, shortening outbreaks and reducing how often they happen. Understanding the mechanics behind these drugs helps explain why timing matters, why daily therapy works differently from outbreak treatment, and why the virus still sticks around even when symptoms disappear.
How Antivirals Stop the Virus From Replicating
The herpes simplex virus hijacks your cells’ machinery to make copies of itself. To do that, it needs to build new strands of viral DNA. The most widely used herpes medications, acyclovir, valacyclovir, and famciclovir, all exploit this step. They mimic one of the building blocks the virus uses to assemble its DNA. When the virus grabs the drug molecule instead of the real building block, the growing DNA chain hits a dead end and can’t be completed. No complete DNA means no new virus particles.
What makes these drugs relatively safe is selectivity. The virus produces its own enzyme, called thymidine kinase, to activate the raw materials it needs for replication. That same enzyme is what converts the medication into its active form inside infected cells. Healthy, uninfected cells barely activate the drug at all, so the medication concentrates its effects where the virus is actively reproducing. This is why side effects tend to be mild for most people.
Differences Between the Three Main Medications
Acyclovir was the first antiviral developed for herpes and remains the foundation of treatment. Its main limitation is poor absorption from the gut. Only about 10 to 20 percent of an oral dose actually reaches your bloodstream, which means you need to take it more frequently throughout the day.
Valacyclovir solves that problem. It’s a “prodrug,” meaning your body rapidly converts it into acyclovir after you swallow it. According to FDA pharmacology data, this conversion happens during its first pass through the intestinal wall and liver, boosting bioavailability to roughly 54.5 percent. That’s about three to five times higher than plain acyclovir, which lets you take fewer doses per day while maintaining effective drug levels.
Famciclovir takes a similar prodrug approach but converts into a different active compound, penciclovir. Penciclovir works through the same DNA chain-termination mechanism, but it lingers inside infected cells longer. Its active form has an intracellular half-life of 10 hours in cells infected with HSV-1 and 20 hours in cells infected with HSV-2, per FDA prescribing data. In practical terms, this also allows for less frequent dosing. All three medications are considered equally effective for most people; the choice usually comes down to convenience and cost.
Episodic Treatment vs. Daily Suppressive Therapy
There are two distinct strategies for using these medications, and they work toward different goals.
Episodic treatment means taking medication at the first sign of an outbreak, ideally during the tingling or burning stage before sores appear. A short course of pills over a few days helps your immune system shut down viral replication faster, which shortens healing time and reduces symptom severity. The earlier you start, the more effective it is. If you wait until sores are fully formed, the benefit shrinks considerably because the virus has already done most of its damage to the skin cells.
Daily suppressive therapy is a different approach entirely. You take a lower dose of medication every day regardless of symptoms. CDC treatment guidelines note that suppressive therapy reduces the frequency of outbreaks by 70 to 80 percent in people who experience frequent recurrences. Beyond fewer outbreaks, daily therapy also reduces viral shedding, the periods when the virus is active on your skin without visible symptoms. This matters because shedding is one of the main ways herpes is transmitted. Daily valacyclovir has been shown to decrease the rate of HSV-2 transmission between sexual partners.
How Topical Treatments Work Differently
Over-the-counter creams like docosanol (sold as Abreva) take a completely different approach from oral antivirals. Instead of targeting the virus’s DNA machinery, docosanol changes the surface of your own cells. The drug gets absorbed into cell membranes and alters their structure in a way that prevents the virus from fusing with the cell and getting inside. Research published in Antiviral Research found that docosanol inhibits the fusion between the viral envelope and the cell’s outer membrane by about 75 percent, effectively locking the door before the virus can enter.
This host-cell-targeting mechanism has one notable advantage: because it doesn’t put direct pressure on the virus to mutate, it’s less likely to drive drug resistance. The tradeoff is that topical treatments only work on the small area of skin where you apply them and are generally less potent than oral antivirals. They’re primarily used for cold sores (oral herpes) rather than genital herpes, and they work best when applied at the very first tingle.
Why the Virus Doesn’t Go Away
Every antiviral medication currently available targets the virus while it’s actively replicating. But herpes has a survival trick: after the initial infection, it retreats into nerve cell clusters near the spine (for genital herpes) or near the base of the skull (for oral herpes) and goes dormant. In this latent state, the virus isn’t making copies of itself, so there’s no replication machinery for the drugs to disrupt. Research in Frontiers in Immunology confirms that acyclovir, valacyclovir, and famciclovir do not eliminate latent herpes, and if therapy is stopped, shedding and symptoms often return.
This is the central limitation of current treatment. The medications are highly effective at controlling active infections but have no way to reach the virus in its hiding place. Your immune system does maintain some surveillance over those dormant virus particles, which is part of why outbreaks tend to become less frequent over the years even without medication. But the latent reservoir remains, which is why herpes is considered a lifelong infection.
Drug Resistance Is Rare but Real
Because these medications depend on the virus’s own thymidine kinase enzyme to become activated, resistance develops when the virus mutates that enzyme so it no longer recognizes the drug. In people with healthy immune systems, this is uncommon. Surveillance data puts resistance rates below 1 percent in the general population, regardless of how long someone has been on treatment.
The picture changes for people with weakened immune systems, such as organ transplant recipients or those undergoing certain cancer treatments. In these groups, the virus replicates more aggressively and has more opportunities to mutate, which drives resistance rates significantly higher. When standard antivirals stop working, doctors turn to alternative medications that bypass thymidine kinase entirely and attack viral DNA replication through a different pathway. These alternatives tend to have more side effects, which is why they’re reserved for resistant cases.
What Medication Timing Actually Looks Like
For a first outbreak, treatment typically lasts 7 to 10 days. First episodes are usually the most severe because your immune system hasn’t built any defenses against the virus yet, so a longer course helps your body catch up. Recurrent outbreaks are shorter and milder on their own, and a 3 to 5 day course of medication can speed healing further if you start at the first symptom.
If you’re on daily suppressive therapy, your doctor will generally reassess once a year. Many people find that after a year or more of suppression, their outbreak frequency has dropped enough to try stopping medication and seeing how things go. Others, particularly those in relationships with uninfected partners, choose to stay on suppressive therapy long-term. The safety profile of these drugs over years of continuous use is well established, and there’s no evidence that long-term use causes the virus to “rebound” worse when you stop.